Song et al. designed a metformin–cisplatin nanoparticle activated by lasers and targets the ligand low-density lipoprotein receptor, which is specific to the hypoxic regions of HNSCC (Song et al., 2020; Zhao et al., 2019). This evidence concerns the gene VLDLR and head and neck squamous cell carcinoma.